Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's condition, medical history, and current clinical guidelines. This resource is not a substitute for professional medical judgment.

H Pylori

Overview

• Definition: Helicobacter pylori (H. pylori) is a Gram-negative, microaerophilic, spiral-shaped bacterium that colonizes the gastric mucosa. It is a major cause of chronic gastritis, peptic ulcer disease (PUD), gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
• Epidemiology:
  • Prevalence: Global prevalence varies significantly, ranging from <20% in developed countries to >80% in developing countries. Worldwide, approximately 50% of the population is infected.
  • Transmission: Primarily acquired in childhood. Routes of transmission are not fully elucidated but are thought to be oral-oral, fecal-oral, or gastro-oral (emesis). Crowded living conditions, poor sanitation, and contaminated water sources are significant risk factors.
  • Demographics: Higher prevalence in lower socioeconomic groups and among older individuals (reflecting cumulative exposure).
• Classification: While H. pylori is a single species, different strains exist with varying virulence factors.
  • CagA (Cytotoxin-associated gene A): Strains positive for CagA are associated with a higher risk of more severe inflammation, peptic ulcers, gastric atrophy, intestinal metaplasia, and gastric cancer.
  • VacA (Vacuolating cytotoxin A): Another important virulence factor, contributing to gastric epithelial damage.

Pathophysiology

• Mechanism:
  1. Colonization: H. pylori survives the acidic gastric lumen by producing large amounts of urease, an enzyme that hydrolyzes urea into ammonia and carbon dioxide. Ammonia buffers the gastric acid, creating a neutral microenvironment around the bacterium.
  2. Motility: Flagella allow the bacterium to move through the mucus layer and adhere to gastric epithelial cells, primarily in the antrum.
  3. Adhesion: Outer membrane proteins (e.g., BabA, SabA) facilitate adherence to specific receptors on gastric epithelial cells, preventing washout.
  4. Inflammation: H. pylori triggers a chronic inflammatory response (gastritis) by recruiting neutrophils, macrophages, and lymphocytes. This involves activation of NF-κB, production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α), and reactive oxygen species.
  5. Toxins: Virulence factors like CagA (injected into host cells via a type IV secretion system, disrupting cell signaling and promoting inflammation/proliferation) and VacA (induces vacuolation, mitochondrial damage, and apoptosis in host cells) contribute to tissue damage and immune evasion.
  6. Gastric Acid Secretion Alteration: H. pylori infection alters gastrin and somatostatin regulation, typically leading to increased gastrin release (especially with antral-predominant gastritis) and reduced somatostatin, resulting in increased acid secretion in some individuals (duodenal ulcer risk) and decreased acid secretion (atrophic gastritis, gastric cancer risk) in others.
• Risk Factors:
  • Socioeconomic status (lower income, crowded living).
  • Poor sanitation and hygiene.
  • Contaminated food and water.
  • Family history of H. pylori infection or associated diseases (e.g., gastric cancer).
  • Living in or immigrating from high-prevalence areas.
• Protective Factors:
  • Improved hygiene and sanitation.
  • Access to clean drinking water.
  • Good dietary practices (e.g., certain probiotics, although not consistently proven for prevention).

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Most H. pylori infections are asymptomatic. When symptomatic, they are typically related to associated conditions:
  • Chronic Gastritis: Often asymptomatic, but can cause vague upper abdominal discomfort or dyspepsia.
  • Peptic Ulcer Disease (PUD):
    • Duodenal Ulcer: Epigastric pain that is often burning, gnawing, or aching, typically relieved by food or antacids, and recurs 2-4 hours after meals or at night.
    • Gastric Ulcer: Epigastric pain that may be worsened by food.
  • Functional Dyspepsia: H. pylori eradication can alleviate symptoms in a subset of patients.
• Early Signs: Vague, non-specific dyspeptic symptoms (epigastric discomfort, bloating, nausea, early satiety).
• Advanced Signs: Symptoms related to complications:
  • Gastrointestinal Bleeding: Hematemesis, melena, coffee-ground emesis, syncope, pallor, fatigue (due to anemia).
  • Gastric Outlet Obstruction: Persistent vomiting (especially undigested food), early satiety, weight loss.
  • Perforation: Sudden, severe, generalized abdominal pain, guarding, rigidity (peritonitis).
  • Gastric Cancer/MALT Lymphoma: Unexplained weight loss, progressive dysphagia, early satiety, persistent vomiting, palpable abdominal mass, fatigue (anemia).
• Atypical Presentations:
  • Iron Deficiency Anemia (IDA): Especially in the absence of overt gastrointestinal bleeding, due to chronic blood loss or impaired iron absorption.
  • Immune Thrombocytopenic Purpura (ITP): A subset of ITP patients experience platelet count improvement after H. pylori eradication.

Physical Examination

• Inspection:
  • Generally unremarkable in asymptomatic or mild cases.
  • Pallor may indicate anemia (chronic blood loss).
  • Signs of weight loss or muscle wasting in advanced malignancy or severe complications.
  • Distended abdomen or visible peristalsis in gastric outlet obstruction.
• Palpation:
  • Mild epigastric tenderness may be present in patients with active gastritis or peptic ulcers.
  • Rebound tenderness, guarding, rigidity, and absent bowel sounds suggest peritonitis (e.g., ulcer perforation).
  • Palpable abdominal mass may indicate advanced gastric cancer or MALT lymphoma.
• Special Tests: None specific for H. pylori infection itself. Physical exam focuses on identifying complications.

Diagnostic Approach

History Taking

• Key Questions:
  • Dyspepsia: Onset, character (burning, gnawing), location (epigastric), radiation, severity, aggravating/alleviating factors (food, antacids).
  • Alarm Symptoms: Weight loss, dysphagia, odynophagia, recurrent vomiting, GI bleeding (hematemesis, melena, coffee-ground emesis), anemia, palpable mass.
  • Medication History: NSAID or aspirin use (significant confounder for PUD).
  • Prior H. pylori history: Previous testing, treatment regimens, and eradication confirmation.
  • Family History: Gastric cancer, peptic ulcer disease.
  • Geographical/Environmental: Travel history, living conditions, areas of high prevalence.
• Red Flags: The presence of any alarm symptom necessitates prompt upper endoscopy due to increased risk of malignancy or serious complications.
  • Unintentional weight loss >10% body weight
  • Progressive dysphagia or odynophagia
  • Recurrent or persistent vomiting
  • Evidence of gastrointestinal bleeding (hematemesis, melena, iron deficiency anemia)
  • Palpable abdominal mass or lymphadenopathy
  • Family history of gastric cancer in a first-degree relative
  • New-onset dyspepsia in patients ≥ 60 years old (threshold may be lower in some guidelines, e.g., ≥50 years old in Asian populations).

Laboratory Tests

• First-Line (Non-invasive for initial diagnosis or eradication confirmation):
  • Urea Breath Test (UBT): Highly accurate (sensitivity >95%, specificity >95%). Patient ingests urea labeled with ${ }^{13}C$ or ${ }^{14}C$. If H. pylori is present, urease breaks down urea, releasing labeled $\mathrm{CO_2}$, which is detected in breath.
    • Preparation: Discontinue PPIs for 1-2 weeks and antibiotics/bismuth for 4 weeks prior to testing to avoid false negatives.
  • Stool Antigen Test (SAT): High accuracy (sensitivity >90%, specificity >90%), detecting H. pylori antigens in stool.
    • Preparation: Same as UBT regarding PPIs, antibiotics, and bismuth.
  • Serology (antibody test): Detects IgG antibodies to H. pylori.
    • Limitations: Cannot distinguish between active and past infection as antibodies can persist for years after successful eradication. Not recommended for confirming eradication. Useful for screening in high-prevalence populations or when UBT/SAT are not feasible (e.g., recent antibiotic use, active GI bleeding).
• Confirmatory (Invasive, typically via endoscopy with biopsy): Indicated for patients with alarm symptoms, age-appropriate screening for gastric cancer, or prior to initiating long-term acid suppression.
  • Rapid Urease Test (RUT): Biopsy samples from gastric antrum and body are placed in a urea-containing medium with a pH indicator. H. pylori urease activity rapidly changes the color.
    • Limitations: False negatives possible if bacterial load is low, active GI bleeding, or recent PPI/antibiotic use.
  • Histology: Gold standard. Biopsies (antrum and body, minimum of 2 from each site) stained with H&E, Giemsa, Warthin-Starry, or immunohistochemical stains to visualize bacteria and assess inflammation, atrophy, intestinal metaplasia, and dysplasia.
    • Preparation: Discontinue PPIs for 1-2 weeks, antibiotics/bismuth for 4 weeks.
  • Culture: Requires specialized facilities. Primarily used for antibiotic susceptibility testing in cases of treatment failure or high local resistance rates.
  • Molecular Methods (e.g., PCR): Can detect H. pylori DNA and resistance genes (e.g., clarithromycin resistance) in biopsy samples or stool. Increasingly used for guiding therapy, especially after treatment failure.
• Monitoring: Eradication should be confirmed with a UBT or SAT at least 4 weeks after completion of therapy, and at least 2 weeks after discontinuing PPIs. Serology is not recommended for confirming eradication.

Imaging

• Recommended:
  • Upper Endoscopy with Biopsy: This is the primary "imaging" for direct visualization of the gastric mucosa and collection of biopsies for definitive diagnosis (histology, RUT, culture) and assessment of associated pathologies (ulcers, gastritis, cancer). Indicated for patients with alarm symptoms, new-onset dyspepsia at older age, or for evaluation of gastric MALT lymphoma. It is not typically recommended for the sole purpose of diagnosing H. pylori in uncomplicated dyspepsia without alarm symptoms (use "test-and-treat" strategy).
• Advanced:
  • CT Scan / MRI: Not used for diagnosing H. pylori itself. May be used to stage gastric cancer, assess complications of PUD (e.g., perforation, obstruction), or evaluate MALT lymphoma spread.
  • Endoscopic Ultrasound (EUS): Useful for local staging of gastric cancer or MALT lymphoma, assessing depth of invasion.

Management

Acute Management

• Acute management is generally focused on complications rather than the infection itself.
  • Immediate (for GI Bleeding): Hemodynamic stabilization (IV fluids, blood transfusion), endoscopy for hemostasis, PPI infusion.
  • Emergency (for Perforation): Surgical repair, broad-spectrum antibiotics, fluid resuscitation.
  • Gastric Outlet Obstruction: Nasogastric decompression, fluid/electrolyte correction, endoscopy with balloon dilation if due to benign stricture, or surgery.
  • H. pylori eradication can be initiated once the acute complication is managed and the patient is stable.

Chronic Management

• Pharmacological (Eradication Therapy): The cornerstone of management is to eradicate the bacterium using combination therapy. Most regimens include a proton pump inhibitor (PPI) and two or three antibiotics. Treatment duration is typically 10-14 days. 14-day regimens are generally superior to 7-10 day regimens.
  • Standard Triple Therapy: (Less effective due to increasing clarithromycin resistance, generally discouraged as first-line unless clarithromycin susceptibility is confirmed or resistance rates are known to be low <15%).
    • Components: PPI + Clarithromycin + Amoxicillin OR Metronidazole.
    • Dosages (BID for 14 days):
      • PPI (e.g., Omeprazole 20 mg, Esomeprazole 20 mg, Lansoprazole 30 mg, Pantoprazole 40 mg, Rabeprazole 20 mg)
      • Clarithromycin 500 mg
      • Amoxicillin 1000 mg (or Metronidazole 500 mg if penicillin allergy)
  • Bismuth Quadruple Therapy: (Preferred first-line in areas with high clarithromycin resistance, or as second-line therapy).
    • Components: PPI + Bismuth + Metronidazole + Tetracycline.
    • Dosages (QID for Bismuth/Tetracycline, BID for PPI/Metronidazole for 10-14 days):
      • PPI (standard dose, BID)
      • Bismuth subsalicylate/subcitrate 120-140 mg QID
      • Metronidazole 250-500 mg TID or QID (or 500 mg BID with 14-day duration)
      • Tetracycline 500 mg QID (or Doxycycline 100 mg BID)
  • Concomitant Therapy: (Strong first-line option, especially in areas with moderate clarithromycin resistance).
    • Components: PPI + Clarithromycin + Amoxicillin + Metronidazole (or Tinidazole).
    • Dosages (BID for 10-14 days):
      • PPI (standard dose, BID)
      • Clarithromycin 500 mg BID
      • Amoxicillin 1000 mg BID
      • Metronidazole 500 mg BID (or Tinidazole 500 mg BID)
  • Sequential Therapy: (Used in some regions, but evidence suggests concomitant or bismuth quadruple may be superior).
    • Components: PPI + Amoxicillin for 5 days, followed by PPI + Clarithromycin + Metronidazole for another 5 days. Total 10 days.
    • Dosages:
      • Days 1-5: PPI (standard dose, BID) + Amoxicillin 1000 mg BID
      • Days 6-10: PPI (standard dose, BID) + Clarithromycin 500 mg BID + Metronidazole 500 mg BID
  • Hybrid Therapy: (Similar to sequential, but total 14 days)
    • Components: PPI + Amoxicillin for 7 days, then PPI + Amoxicillin + Clarithromycin + Metronidazole for another 7 days.
    • Dosages:
      • Days 1-7: PPI (standard dose, BID) + Amoxicillin 1000 mg BID
      • Days 8-14: PPI (standard dose, BID) + Amoxicillin 1000 mg BID + Clarithromycin 500 mg BID + Metronidazole 500 mg BID
  • Levofloxacin Triple Therapy: (Often used as a second-line or rescue therapy due to quinolone resistance concerns).
    • Components: PPI + Amoxicillin + Levofloxacin.
    • Dosages (BID for 10-14 days):
      • PPI (standard dose, BID)
      • Amoxicillin 1000 mg BID
      • Levofloxacin 500 mg QD (or 250 mg BID)
• Non-pharmacological:
  • Diet: No specific dietary restrictions are universally recommended, but patients with active ulcers may benefit from avoiding foods that exacerbate symptoms.
  • Lifestyle: Smoking cessation, avoidance of alcohol (especially if PUD present), and NSAID avoidance are crucial for healing ulcers and preventing recurrence, but do not eradicate H. pylori.
• Monitoring:
  • Eradication Confirmation: Essential. Performed 4 weeks post-treatment using UBT or SAT. PPIs should be withheld for 1-2 weeks prior to testing.
  • Follow-up Endoscopy: Recommended for gastric ulcers to confirm healing and exclude underlying malignancy (e.g., 6-8 weeks post-eradication). Not typically needed for duodenal ulcers if uncomplicated.
  • Long-term Surveillance: For patients with gastric atrophy or intestinal metaplasia, surveillance endoscopy may be recommended based on extent and severity.

Treatment Algorithms

• First-Line:
  • Guideline Recommendations (e.g., ACG, Maastricht VI):
    • Clarithromycin Resistance Rate < 15% AND low dual resistance to clarithromycin and metronidazole: Clarithromycin Triple Therapy (PPI + Clarithromycin + Amoxicillin or Metronidazole) for 14 days.
    • Clarithromycin Resistance Rate ≥ 15% (or unknown):
      • Bismuth Quadruple Therapy (PPI + Bismuth + Metronidazole + Tetracycline) for 10-14 days. This is often preferred as first-line due to its high efficacy regardless of clarithromycin resistance.
      • Concomitant Therapy (PPI + Clarithromycin + Amoxicillin + Metronidazole) for 10-14 days.
      • Non-bismuth Quadruple Therapy (PPI + Amoxicillin + Metronidazole + Tetracycline) as an alternative if bismuth is unavailable or contraindicated.
• Second-Line (after first-line failure):
  • If clarithromycin triple therapy failed:
    • Bismuth Quadruple Therapy for 10-14 days.
    • Levofloxacin Triple Therapy (PPI + Amoxicillin + Levofloxacin) for 10-14 days (ensure no prior quinolone exposure or resistance).
  • If bismuth quadruple therapy failed:
    • Levofloxacin Triple Therapy.
    • Consider culture and susceptibility testing to guide therapy, especially after two failures.
• Refractory Cases (after two or more failures):
  • Referral to a specialist.
  • Culture and Susceptibility Testing: Essential to identify specific antibiotic resistances.
  • Tailored Regimens: Based on susceptibility results, e.g., rifabutin-based triple therapy, high-dose dual therapy (PPI + amoxicillin), or other novel combinations. Often 14 days, possibly longer.

Complications

• Common:
  • Chronic Gastritis: Can be asymptomatic or cause dyspepsia.
  • Peptic Ulcer Disease (PUD): Duodenal ulcers (more common) and gastric ulcers.
• Serious:
  • Gastrointestinal Bleeding: From ulcers (hematemesis, melena, severe anemia).
  • Perforation: Ulcer penetrating through the gastric or duodenal wall, leading to peritonitis, a surgical emergency.
  • Gastric Outlet Obstruction: Due to edema, inflammation, or scarring from ulcers in the pyloric or duodenal region.
  • Gastric Adenocarcinoma: H. pylori is a Class I carcinogen. It accounts for up to 90% of non-cardia gastric cancers. The Correa cascade (inflammation -> atrophy -> intestinal metaplasia -> dysplasia -> cancer) is often involved.
  • Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: A low-grade B-cell lymphoma. Eradication of H. pylori can lead to complete regression in a significant proportion of early-stage cases.
  • Iron Deficiency Anemia (IDA): Often refractory to oral iron supplementation until H. pylori is eradicated.
  • Immune Thrombocytopenic Purpura (ITP): A subset of patients experience improved platelet counts with eradication.
• Long-term:
  • Persistent inflammation.
  • Increased risk of recurrence of PUD if not eradicated.
  • Continued risk of gastric cancer or MALT lymphoma if infection persists or if pre-malignant changes (atrophy, intestinal metaplasia) are advanced.

Prognosis

• Factors:
  • Successful Eradication: The most significant factor for improved prognosis. It leads to ulcer healing, reduced recurrence rates, and decreased risk of gastric cancer and MALT lymphoma.
  • Presence of Complications: Patients presenting with bleeding, perforation, or malignancy have a more guarded prognosis, depending on the severity and stage of the complication.
  • Virulence of Strain: CagA-positive strains are associated with poorer outcomes (higher risk of cancer).
  • Host Genetics: Some genetic polymorphisms (e.g., IL-1B, TNF-α) may influence the inflammatory response and cancer risk.
  • Atrophy/Intestinal Metaplasia: Presence and extent of pre-malignant lesions affect gastric cancer risk even after eradication.
• Survival:
  • Uncomplicated Infection: Excellent prognosis with successful eradication.
  • Peptic Ulcer Disease: Prognosis is good with eradication; recurrence rates drop significantly.
  • Gastric Cancer: Dependent on stage at diagnosis. Eradication reduces risk but does not eliminate it, especially in those with advanced pre-malignant lesions.
  • MALT Lymphoma: Excellent prognosis with eradication in early stages; regression rate is high.
• Quality of Life: Eradication significantly improves symptoms in patients with H. pylori-associated dyspepsia and reduces the burden of recurrent ulcers and their complications.

Prevention

• Primary: Focuses on reducing acquisition of the infection.
  • Improved Sanitation and Hygiene: Access to clean water, proper sewage disposal, and personal hygiene (e.g., handwashing) are crucial, especially in childhood.
  • Reduced Crowding: Decreasing household crowding can reduce transmission.
  • Vaccine Development: Research is ongoing for an H. pylori vaccine, but none are clinically available yet.
• Secondary: Early detection and treatment to prevent disease progression.
  • Test-and-Treat Strategy: For young patients (<60 years or without alarm symptoms) presenting with uninvestigated dyspepsia in high-prevalence areas. This involves non-invasive testing (UBT or SAT) and eradication therapy if positive, without initial endoscopy.
  • Screening: In populations at high risk of gastric cancer (e.g., certain ethnic groups, areas with high prevalence of H. pylori and high gastric cancer incidence, family history of gastric cancer).
• Tertiary: Eradication to prevent complications and recurrence in infected individuals.
  • Eradication for PUD: Prevents ulcer recurrence and associated complications (bleeding, perforation).
  • Eradication for Gastric MALT Lymphoma: Can induce remission in early-stage disease.
  • Eradication for Gastric Cancer Prevention: Recommended for patients with H. pylori infection, particularly those with a family history of gastric cancer, gastric atrophy, or intestinal metaplasia, to reduce the risk of future gastric cancer.

Special Populations

• Pediatric:
  • Diagnosis: Non-invasive tests (UBT, SAT) are preferred. Endoscopy with biopsy is reserved for alarm symptoms or specific indications.
  • Treatment: Regimens often involve a PPI and two antibiotics. Tetracycline is contraindicated in children <8 years old due to dental staining. Bismuth is often avoided in very young children. Dosing is weight-based. First-line is often Amoxicillin + Clarithromycin + PPI.
  • Indications for Testing/Treatment: Recurrent abdominal pain is common and H. pylori is not a primary cause. Testing/treatment generally recommended for PUD, gastric MALT lymphoma, unexplained iron deficiency anemia, or family history of gastric cancer.
• Geriatric:
  • Diagnosis: Consider endoscopy more readily due to higher prevalence of alarm symptoms and gastric cancer risk.
  • Treatment: Polypharmacy and comorbidities (renal/hepatic impairment) necessitate careful drug selection and dosage adjustment. Potential for drug interactions and adverse effects (e.g., C. difficile infection).
  • Benefits of Eradication: May be less pronounced for cancer prevention if infection acquired early in life and significant pre-malignant changes already present, but still beneficial for ulcer prevention.
• Pregnancy:
  • Diagnosis: UBT is preferred. Avoid tests involving radioactive isotopes ($^{14}C$-UBT). Endoscopy is generally avoided unless strong indications.
  • Treatment: Generally deferred until after delivery due to potential fetal risks. If treatment is urgent (e.g., bleeding ulcer), choose agents with good safety profiles: Amoxicillin and Clarithromycin are generally considered safer. Metronidazole should be avoided in the first trimester. Tetracycline, levofloxacin, and bismuth are contraindicated.
• Comorbidities:
  • Renal/Hepatic Impairment: Adjust dosages of certain antibiotics (e.g., clarithromycin, metronidazole, levofloxacin).
  • Allergies: Penicillin allergy requires substituting amoxicillin with metronidazole or other suitable antibiotics.
  • Prior Antibiotic Exposure: Influences choice of first-line therapy (e.g., if recent clarithromycin use, avoid clarithromycin-based regimens).

Clinical Pearls

• Diagnostic:
  • "Test-and-Treat": The recommended strategy for H. pylori in patients under 60 (or age appropriate depending on guidelines/ethnic group) with uninvestigated dyspepsia and no alarm symptoms. Avoids unnecessary endoscopies.
  • "Test-and-Scope": For patients with alarm symptoms or over age cut-off for new-onset dyspepsia, endoscopy with biopsies is indicated.
  • PPI & Antibiotic Washout: Always ensure PPIs are stopped for 1-2 weeks and antibiotics/bismuth for 4 weeks before performing UBT, SAT, or biopsy-based tests to avoid false negatives. Serology is not affected but cannot confirm active infection or eradication.
  • Confirm Eradication: Crucial 4 weeks post-treatment with UBT or SAT for all treated patients, as failure rates are significant.
• Treatment:
  • 14-Day Regimens: Generally preferred over 7 or 10-day regimens for higher eradication rates.
  • Local Resistance Patterns: Be aware of local clarithromycin and metronidazole resistance rates when selecting first-line therapy. Bismuth quadruple therapy is a robust option when resistance data is unavailable or resistance is high.
  • Adherence: Counsel patients on the importance of completing the full course of antibiotics, as poor adherence is a major cause of treatment failure and resistance.
  • Sequential vs. Concomitant: Concomitant therapy often shows higher eradication rates than sequential therapy in many studies.
• Pitfalls:
  • Not Confirming Eradication: Leads to persistent symptoms, complications, and potentially further progression of associated diseases.
  • Re-testing Too Early: Leading to false negative results, unnecessary re-treatment, and patient frustration.
  • Ignoring Alarm Symptoms: Can delay diagnosis of serious underlying conditions like gastric cancer.
  • Using Serology for Eradication Confirmation: Antibodies persist, making serology unreliable for post-treatment assessment.
  • Empiric Re-treatment Without Susceptibility Testing: Increases the risk of further treatment failure and antibiotic resistance.

Recent Updates

• Guidelines:
  • Maastricht VI/Florence Consensus Report (2022): Reaffirms the need for regional tailoring of therapy based on antibiotic resistance. Emphasizes the role of bismuth quadruple therapy and concomitant therapy as first-line options. Stresses the importance of a 14-day treatment duration. Highlights molecular resistance testing (e.g., for clarithromycin) to guide therapy in appropriate settings.
  • American College of Gastroenterology (ACG) Guidelines (2017/Updated): Similar recommendations, emphasizing bismuth quadruple and concomitant therapy as preferred first-line options in most areas of the US due to high clarithromycin resistance.
• Evidence:
  • Increasing Antibiotic Resistance: Growing global resistance to clarithromycin and metronidazole continues to be a major challenge, necessitating a shift away from standard triple therapy in many regions. Levofloxacin resistance is also increasing.
  • Novel Therapies: Research into new antibiotics, vaccine strategies, and alternative eradication approaches (e.g., vonoprazan-based regimens, which are more potent acid suppressants) is ongoing.
  • Probiotics: Certain probiotics (e.g., Lactobacillus, Bifidobacterium, Saccharomyces boulardii) may be used as adjuncts to reduce antibiotic-associated side effects and potentially improve eradication rates, though evidence strength varies.
• Controversies:
  • Role in Functional Dyspepsia: While H. pylori eradication improves symptoms in a subset of functional dyspepsia patients, identifying this subset remains challenging.
  • Optimal Rescue Regimens: The best approach after multiple treatment failures often requires individualized, culture-guided therapy due to complex resistance patterns.
  • Screening for Gastric Cancer Prevention: Debate continues on the cost-effectiveness and feasibility of widespread H. pylori screening and eradication programs in different populations to prevent gastric cancer.

Key References

• Guidelines:
  • Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence Consensus Report. Gut. 2022;71(9):1725-1762.
  • Chey WD, Leontiadis GP, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-239.
  • European Helicobacter and Microbiota Study Group (EHMSG) guidelines (regularly updated).
• Studies:
  • Graham DY. Helicobacter pylori Update: Gastric Cancer, Other Gastric Pathologies and Vaccine Development. Trends Microbiol. 2019;27(1):19-27.
  • Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187-194.
• Reviews:
  • Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-429.
  • Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori Infection. Clin Microbiol Rev. 2006;19(3):449-490.